FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3086728574> ?p ?o ?g. }

• W3086728574 endingPage "230" @default.
• W3086728574 startingPage "221" @default.
• W3086728574 abstract "Systemic lupus erythematosus (SLE) is an autoimmune, multi-system inflammatory disease. Among cytokines involved in SLE pathogenesis, interferons (particularly IFN-α) and interleukin 34 play a pivotal role. Interestingly, the gene signatures of type III (IFN-λ1) and type I IFNs may overlap. Increased levels of IFN-λ also have been reported in SLE.Objectives: The aim of this study was to assess serum levels of IL-34, IFN-λ1, IFN-α and the relationship between these cytokines and clinical and laboratory parameters and response to treatment in a cohort of Egyptian SLE patients.The study included 82 newly diagnosed SLE patients: male 17.1% (n = 14), female 82.9% (n = 68), mean age ±SD: 48.6 ±8.2 and 60 healthy subjects matched by age and gender as a control group. Medical history, physical examination and laboratory tests for confirming SLE diagnosis and assessment of disease activity were collected. The assessment of serum levels of studied cytokines were performed using the ELISA method.All studied patients after first cytokine evaluation were treated with a combination of antimalarial drugs, glucocorticosteroids and/or immunosuppressive drugs with follow-up after six months of treatment.In the SLE group the mean serum levels of IL-34, IFN-α and IFN-λ1 were 175.9 ±125.9 pg/ml, 109.3 ±32.5 pg/ml and 227.9 ±144.8 pg/ml respectively. These cytokine levels were significantly higher in the SLE group than in healthy controls. 39% of SLE patients (n = 32) had SLAM > 6 and 26.8% (n = 22) had SLEDAI >6. There were 21 SLE patients (25.6%) with lupus nephritis.IL-34 and IFN-λ1 were positively correlated with anti-dsDNA antibodies but negatively correlated with C3 complement component (p ≤ 0.05). IL-34, INF-α and IFN-λ1 were significantly higher in lupus nephritis patients, and correlated with poorest response to treatment.IL-34 and IFN-λ1 were correlated with higher SLAM > 6 and SLEDAI > 6 results; there was no such correlation between IFN-α and disease activity.Accumulation of three or more clinical features during follow-up was significantly associated with high levels of studied cytokines. Triple high positivity was found in 17 patients (20.7%) and correlated with presence of anti-dsDNA antibodies, low levels of C3 component of complement and lupus nephritis.SLE patients with high serum levels of IL-34, IFN-α and IFN-λ1 more often had lupus nephritis and poor response to immunosuppressive treatment.The triple cytokine elevation was strongly associated with higher disease activity. These results may indicate the need to distinguish this group of patients with such aggressive phenotype and consider targeted multi-therapy." @default.
• W3086728574 created "2020-09-21" @default.
• W3086728574 creator A5028865213 @default.
• W3086728574 creator A5052214861 @default.
• W3086728574 date "2020-08-31" @default.
• W3086728574 modified "2023-10-02" @default.
• W3086728574 title "Impact of IL-34, IFN-α and IFN-λ1 on activity of systemic lupus erythematosus in Egyptian patients" @default.
• W3086728574 cites W1679569810 @default.
• W3086728574 cites W1961276029 @default.
• W3086728574 cites W1965672602 @default.
• W3086728574 cites W1991636716 @default.
• W3086728574 cites W1994292458 @default.
• W3086728574 cites W2003863305 @default.
• W3086728574 cites W2022126078 @default.
• W3086728574 cites W2042312470 @default.
• W3086728574 cites W2050386938 @default.
• W3086728574 cites W2056273927 @default.
• W3086728574 cites W2061462004 @default.
• W3086728574 cites W2065907531 @default.
• W3086728574 cites W2075715794 @default.
• W3086728574 cites W2076093906 @default.
• W3086728574 cites W2078895122 @default.
• W3086728574 cites W2096250597 @default.
• W3086728574 cites W2102309886 @default.
• W3086728574 cites W2111534148 @default.
• W3086728574 cites W2115953810 @default.
• W3086728574 cites W2122801249 @default.
• W3086728574 cites W2127198764 @default.
• W3086728574 cites W2143973423 @default.
• W3086728574 cites W2155952957 @default.
• W3086728574 cites W2166617377 @default.
• W3086728574 cites W2167446675 @default.
• W3086728574 cites W2168888135 @default.
• W3086728574 cites W2177646845 @default.
• W3086728574 cites W2209458064 @default.
• W3086728574 cites W2302024964 @default.
• W3086728574 cites W2308059048 @default.
• W3086728574 cites W2513312047 @default.
• W3086728574 cites W2553189291 @default.
• W3086728574 cites W2554739988 @default.
• W3086728574 cites W2562396666 @default.
• W3086728574 cites W2626177916 @default.
• W3086728574 cites W2756895562 @default.
• W3086728574 doi "https://doi.org/10.5114/reum.2020.98434" @default.
• W3086728574 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7477477" @default.
• W3086728574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32921829" @default.
• W3086728574 hasPublicationYear "2020" @default.
• W3086728574 type Work @default.
• W3086728574 sameAs 3086728574 @default.
• W3086728574 citedByCount "8" @default.
• W3086728574 countsByYear W30867285742021 @default.
• W3086728574 countsByYear W30867285742022 @default.
• W3086728574 countsByYear W30867285742023 @default.
• W3086728574 crossrefType "journal-article" @default.
• W3086728574 hasAuthorship W3086728574A5028865213 @default.
• W3086728574 hasAuthorship W3086728574A5052214861 @default.
• W3086728574 hasBestOaLocation W30867285741 @default.
• W3086728574 hasConcept C126322002 @default.
• W3086728574 hasConcept C159654299 @default.
• W3086728574 hasConcept C203014093 @default.
• W3086728574 hasConcept C2775915377 @default.
• W3086728574 hasConcept C2776178377 @default.
• W3086728574 hasConcept C2776912625 @default.
• W3086728574 hasConcept C2778690821 @default.
• W3086728574 hasConcept C2779075594 @default.
• W3086728574 hasConcept C2779134260 @default.
• W3086728574 hasConcept C2780942790 @default.
• W3086728574 hasConcept C71924100 @default.
• W3086728574 hasConcept C72563966 @default.
• W3086728574 hasConceptScore W3086728574C126322002 @default.
• W3086728574 hasConceptScore W3086728574C159654299 @default.
• W3086728574 hasConceptScore W3086728574C203014093 @default.
• W3086728574 hasConceptScore W3086728574C2775915377 @default.
• W3086728574 hasConceptScore W3086728574C2776178377 @default.
• W3086728574 hasConceptScore W3086728574C2776912625 @default.
• W3086728574 hasConceptScore W3086728574C2778690821 @default.
• W3086728574 hasConceptScore W3086728574C2779075594 @default.
• W3086728574 hasConceptScore W3086728574C2779134260 @default.
• W3086728574 hasConceptScore W3086728574C2780942790 @default.
• W3086728574 hasConceptScore W3086728574C71924100 @default.
• W3086728574 hasConceptScore W3086728574C72563966 @default.
• W3086728574 hasIssue "4" @default.
• W3086728574 hasLocation W30867285741 @default.
• W3086728574 hasLocation W30867285742 @default.
• W3086728574 hasLocation W30867285743 @default.
• W3086728574 hasLocation W30867285744 @default.
• W3086728574 hasOpenAccess W3086728574 @default.
• W3086728574 hasPrimaryLocation W30867285741 @default.
• W3086728574 hasRelatedWork W1503288527 @default.
• W3086728574 hasRelatedWork W1968509366 @default.
• W3086728574 hasRelatedWork W2056065139 @default.
• W3086728574 hasRelatedWork W2093868050 @default.
• W3086728574 hasRelatedWork W2155353257 @default.
• W3086728574 hasRelatedWork W2375289158 @default.
• W3086728574 hasRelatedWork W2918673775 @default.
• W3086728574 hasRelatedWork W3031932532 @default.
• W3086728574 hasRelatedWork W4309888487 @default.
• W3086728574 hasRelatedWork W4313386619 @default.

• next